Compare GRABW & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRABW | CGEN |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | Singapore | Israel |
| Employees | 11267 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 188.2M |
| IPO Year | N/A | 2001 |
| Metric | GRABW | CGEN |
|---|---|---|
| Price | $0.08 | $2.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 23.8K | ★ 216.3K |
| Earning Date | 02-21-2025 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,686,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $112.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.65 | N/A |
| 52 Week Low | $0.07 | $1.13 |
| 52 Week High | $0.60 | $2.38 |
| Indicator | GRABW | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 57.76 |
| Support Level | N/A | $1.47 |
| Resistance Level | $0.11 | $2.35 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 33.18 | 61.35 |
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.